5 succinct key points:
  1. We discovered a statistically significant association between head and facial lesions and the diagnosis of PHACE syndrome.
  2. 98% of our patients received a daily propanolol dose of 2 mg/kg, and the average duration of propranolol treatment was approximately 11 months.
  3. Propranolol treatment yielded a positive response in 97% of our patients, with 80% experiencing nearly complete or complete improvement during the initial treatment cycle.
  4. The likelihood of residual lesion proliferation is higher when propranolol therapy is discontinued at earlier stages of propanolol response compared to complete response. This finding underscores the importance of early intervention and vigilant post-treatment monitoring to prevent regrowth.
  5. An intriguing aspect of our study is the potential role of a family history of hemangiomas or cardiac abnormalities as a risk factor for requiring a second propranolol cycle.